Targeted Oncology » Chronic Lymphocytic Leukemia
28 FOLLOWERS
Articles on Chronic Lymphocytic Leukemia. Through our digital and print media platforms, Targeted Healthcare Communications offers a dedicated website and publication as well as a number of multichannel programs focused on precision medicine in oncology.
Targeted Oncology » Chronic Lymphocytic Leukemia
7M ago
Jennifer R. Brown, MD, PhD, discusses the unmet needs for patients with chronic lymphocytic leukemia that are treated with zanubrutinib ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
9M ago
An expert oncologist reviews the MURANO trial of venetoclax plus rituximab in patients with relapsed/refractory CLL and discusses MRD as a parameter of treatment response ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
9M ago
Jennifer R. Brown, MD, PhD, discusses the mechanism of action of zanubrutinib and how it differs from other Bruton’s tyrosine kinase inhibitors ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
9M ago
Susan M. O’Brien, MD, discusses the long-term results of the ELEVATE TN trial in patients with previously untreated chronic lymphocytic leukemia ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
1y ago
Zanubrutinib has been granted FDA approval for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
1y ago
In an interview with Targeted Oncology, Carolyn Owen, MD, discussed findings from the GLOW study of elderly/unfit patients with chronic lymphocytic leukemia that were presented at SOHO 2022 ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
1y ago
Topline results from the phase 2 TRANSCEND CLL 004 trial hint that lisocabtagene maraleucel may be active in relapsed or refractory chronic lymphocytic leukemia ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
1y ago
Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma ..read more
Targeted Oncology » Chronic Lymphocytic Leukemia
1y ago
Phase 1 clinical trial data shows that BGB-11417 may induce response and lead to minimal residual disease negativity in patients with chronic lymphocytic leukemia ..read more